Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baloxavir Marboxil in high-risk influenza
NCT02949011Phase 3Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jan 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of baloxavir marboxil in influenza, sponsored by Shionogi & Co., Ltd. Primary endpoint: Time to Improvement of Influenza Symptoms at Day 14. Started Jan 2017; status: completed.
02
Drugs
baloxavir marboxil
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02949011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02949011.